PAVmed
PAVM
3 hedge funds and large institutions have $7.31K invested in PAVmed in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$318K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.36K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $4K | +$6.36K | +1 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $3K | +$6.36K | +1 | New |
|
|
LCS
3
Levin Capital Strategies
New York
| $314 | +$318K | +50 | New |
|
PAVM Hedge Fund Activity: Q3 2016 in Review
3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q3 2016, worth a combined $7.31K.
Buyers outnumbered sellers: 3 funds opened new PAVM positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Levin Capital Strategies, opening a new position worth an estimated $318K.
- 3 institutional investors held PAVmed (PAVM) as of Q3 2016, up from 0 in Q2 2016.
- Funds reported $7.31K of PAVmed stock for Q3 2016.
- 3 funds opened new PAVmed positions in Q3 2016 and 0 closed out, a net change of +3 holders.
- The largest PAVmed buyer in Q3 2016 was Levin Capital Strategies, an estimated $318K added.
Based on aggregated 13F filings for Q3 2016.